Trial Profile
c-TRAK TN: A Randomised Trial Utilising ctDNA Mutation Tracking to Detect Minimal Residual Disease and Trigger Intervention in Patients With Moderate and High Risk Early Stage Triple Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Advanced breast cancer; Early breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms c-TRAK-TN
- 21 Sep 2023 Planned End Date changed from 31 Dec 2024 to 31 Mar 2024.
- 21 Sep 2023 Status changed from completed to active, no longer recruiting.
- 02 Jan 2023 Status changed from active, no longer recruiting to completed.